# Hanmi Pharmaceutical Company Limited trials: 191 (2026)

ClinicalTrials.gov lists 191 trials with Hanmi Pharmaceutical Company Limited as lead sponsor, 12 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Hanmi Pharmaceutical Company Limited: 191 rows for $9.55, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/hanmi-pharmaceutical-company-limited

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 191
- Recruiting or not yet: 12
- Read on: November 19, 2026

## Trials

The 25 newest of 191, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 16, 2026 | NCT07939087 | A Study to Evaluate the Pharmacokinetics and Safety Between HIP2604 and RLD2606 in Healthy Volunteers | Hanmi Pharmaceutical Company Limited | Phase 1 | Not yet recruiting | Healty Volunteers | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07939087) |
| October 27, 2026 | NCT07899073 | A Study to Evaluate Efficacy and Safety of HIP2602 in Erectile Dysfunction Patients | Hanmi Pharmaceutical Company Limited | Phase 3 | Recruiting | Erectile Dysfunction | 225 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07899073) |
| August 25, 2026 | NCT07784296 | Effectiveness and Safety of Sequential Triple Combination Therapy (Amlodipine/Losartan/Chlorthalidone) in Korean Patients With Hypertension | Hanmi Pharmaceutical Company Limited | Observational | Recruiting | Hypertension | 3,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07784296) |
| June 22, 2026 | NCT07660796 | A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension | Hanmi Pharmaceutical Company Limited | Phase 3 | Not yet recruiting | Hypertension | 256 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07660796) |
| April 14, 2026 | NCT07527650 | Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus | Hanmi Pharmaceutical Company Limited | Phase 2 | Recruiting | Type 2 Diabetes Mellitus, T2DM | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07527650) |
| March 4, 2026 | NCT07449754 | Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma | Hanmi Pharmaceutical Company Limited | Phase 2 | Recruiting | Advanced or Metastatic Melanoma | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07449754) |
| January 30, 2026 | NCT07379333 | A Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and... | Hanmi Pharmaceutical Company Limited | Phase 3 | Recruiting | Type 2 Diabetes | 118 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07379333) |
| December 22, 2025 | NCT07297693 | A Study to Evaluate the Pharmacokinetics and Safety Between HIP2503 and HCP1306 in Healthy Volunteers | Hanmi Pharmaceutical Company Limited | Phase 1 | Not yet recruiting | Healthy | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07297693) |
| October 22, 2025 | NCT07219589 | A Single and Multiple Ascending Dose Study of HM17321 in Healthy and Obese Participants | Hanmi Pharmaceutical Company Limited | Phase 1 | Recruiting | Obesity, Obese | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07219589) |
| October 3, 2025 | NCT07205900 | Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus | Hanmi Pharmaceutical Company Limited | Phase 2 | Active not recruiting | Obese, Obesity | 267 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07205900) |
| December 9, 2024 | NCT06724016 | Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors | Hanmi Pharmaceutical Company Limited | Phase 1 | Recruiting | Advanced or Metastatic Solid Tumors | 292 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06724016) |
| September 19, 2024 | NCT06595004 | A Study to Evaluate the Efficacy and Safety of HCP1004 in Chronic Low-Back Pain Patients | Hanmi Pharmaceutical Company Limited | Phase 3 | Completed | Chronic Low-back Pain | 310 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06595004) |
| July 24, 2024 | NCT06518122 | A Study to Evaluate the Drug-drug Interaction and Safety Between HCP1306, RLD2302 and RLD2102 in Healthy Volunteers | Hanmi Pharmaceutical Company Limited | Phase 1 | Completed | Healthy | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06518122) |
| July 1, 2024 | NCT06481098 | A Phase 1 Study to Assess HM15275 in Healthy and Obese Subjects. | Hanmi Pharmaceutical Company Limited | Phase 1 | Completed | Obesity | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06481098) |
| May 31, 2024 | NCT06438172 | A Study to Evaluate Efficacy and Safety of HCP1803 Compared to RLD2001-1 in Patients with Essential Hypertension | Hanmi Pharmaceutical Company Limited | Phase 3 | Completed | Hypertension | 249 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06438172) |
| April 10, 2024 | NCT06357910 | A Study to Evaluate the Pharmacokinetics and Safety Between HCP2303 and Co-administration of Each Component in Healthy Volunteers Under Fed... | Hanmi Pharmaceutical Company Limited | Phase 1 | Completed | Healthy | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06357910) |
| April 3, 2024 | NCT06346184 | A Study to Evaluate the Pharmacokinetics and Safety Between HCP2303 and Co-administration of Each Component in Healthy Volunteers | Hanmi Pharmaceutical Company Limited | Phase 1 | Completed | Healthy | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06346184) |
| January 31, 2024 | NCT06234397 | Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors | Hanmi Pharmaceutical Company Limited | Phase 1 | Recruiting | Advanced or Metastatic Solid Tumors | 216 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06234397) |
| December 18, 2023 | NCT06174779 | A Study to Evaluate Efficacy and Safety of HM11260C in Adult Obesity Patients Without Diabetes Mellitus | Hanmi Pharmaceutical Company Limited | Phase 3 | Completed | Obesity | 448 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06174779) |
| December 18, 2023 | NCT06174766 | A Study to Evaluate Efficacy and Safety of HGP2304 in Essential Hypertension Patients | Hanmi Pharmaceutical Company Limited | Phase 3 | Completed | Hypertension | 356 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06174766) |
| May 17, 2023 | NCT05862090 | A Study to Evaluate the Drug-drug Interaction and Safety of RLD2301 and RLD2007 in Healthy Volunteers | Hanmi Pharmaceutical Company Limited | Phase 1 | Completed | Healthy Volunteers | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05862090) |
| February 21, 2023 | NCT05737082 | A Study to Evaluate the Pharmacokinetics and Safety Between HCP2201 and Co-administration of Each Component in Healty Male Volunteers | Hanmi Pharmaceutical Company Limited | Phase 1 | Completed | Healthy | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05737082) |
| February 10, 2023 | NCT05723549 | A Study to Evaluate the PK, Safety and Tolerability of HCP1803. | Hanmi Pharmaceutical Company Limited | Phase 1 | Completed | Healthy | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05723549) |
| February 3, 2023 | NCT05711381 | Phase 1 Study of PK and Safety of HM15912 (Sonefpeglutide) in Subjects With Normal and Severe Kidney Function | Hanmi Pharmaceutical Company Limited | Phase 1 | Completed | Renal Impairment | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05711381) |
| December 19, 2022 | NCT05656092 | A Study to Evaluate the Effiacy and Safety of HIP0612 in Patients With Gastric Ulcer | Hanmi Pharmaceutical Company Limited | Phase 3 | Completed | Gastric Ulcer | 199 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05656092) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 107 |
| Phase 1/2 | 5 |
| Phase 2 | 21 |
| Phase 3 | 38 |
| Phase 4 | 9 |
| Observational | 11 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 156 |
| Unknown | 15 |
| Recruiting | 9 |
| Terminated | 5 |
| Not yet recruiting | 3 |
| Active not recruiting | 3 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Hypertension | 25 |
| Diabetes Mellitus | 8 |
| Diabetes Mellitus, Type 2 | 8 |
| Erectile Dysfunction | 6 |
| Prostatic Hyperplasia | 6 |
| Obesity | 6 |
| Hyperlipidemias | 6 |
| Dyslipidemias | 4 |
| Carcinoma, Non-Small-Cell Lung | 4 |
| Asthma | 4 |
| Stomach Neoplasms | 3 |
| Rhinitis, Allergic, Perennial | 3 |
| Arthritis, Rheumatoid | 2 |
| Non-alcoholic Fatty Liver Disease | 2 |
| Breast Neoplasms | 2 |
| Neoplasms | 2 |
| Abdominal obesity metabolic syndrome | 1 |
| Rhinitis | 1 |
| Diabetes Mellitus, Type 1 | 1 |
| Neoplasm Metastasis | 1 |
| Hypertension, Pulmonary | 1 |
| Dwarfism, Pituitary | 1 |
| Short Bowel Syndrome | 1 |
| Urinary Bladder, Overactive | 1 |
| Cognitive Dysfunction | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Medical law firms in the United States](https://specstream.ai/data/businesses/medical-law-firms/united-states)
- [Argentine restaurants in the United States](https://specstream.ai/data/businesses/argentine-restaurants/united-states)
- [Hyperbaric medicine centers in the United States](https://specstream.ai/data/businesses/hyperbaric-medicine-centers/united-states)
- [Turkish restaurants in the United States](https://specstream.ai/data/businesses/turkish-restaurants/united-states)
- [Financial services firms in the United States](https://specstream.ai/data/businesses/financial-services-firms/united-states)
